Growth inhibitory effect of adriamycin conjugated to single-chain antibody on human lung adenocarcinoma in vitro.
- Author:
Wen-tao YUE
1
;
Bai-tang LAI
;
Hui WANG
;
Xu-ping ZHAN
;
Yue WANG
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; immunology; pathology; Cell Line, Tumor; Cell Proliferation; drug effects; Colony-Forming Units Assay; Doxorubicin; administration & dosage; pharmacology; Humans; Immunoconjugates; pharmacology; Immunoglobulin Variable Region; chemistry; pharmacology; Lung Neoplasms; immunology; pathology
- From: Chinese Journal of Oncology 2004;26(12):718-721
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the growth inhibitory effect of adriamycin (ADM) conjugated to an anti-lung cancer single-chain antibody (ScFv) 2A7-1 on lung adenocarcinoma cell line A2 in vitro.
METHODS2A7-1 cell culture medium was concentrated by ultra-filtration (with Amicon P10Z filter), and soluble ScFv was purified using RPAS purification kit. ADM was conjugated to 2A7-1 by glutaraldehyde. A(280) and A(490) of the conjugate 2A7-1-ADM were determined by spectrophotometry and the molar ratio of 2A7-1 to ADM was calculated. Immunoreactivity of the conjugate was detected by immunohistochemistry. Its growth inhibitory effect on lung adenocarcinoma cell line A2 was determined by colony formation assay in vitro.
RESULTSThe molar ratio of 2A7-1 to ADM was 1:3.2. The conjugate strongly reacted with A2 cell. Its growth inhibitory effect on A2 cells was 4 times as potent as ADM.
CONCLUSIONAdriamycin conjugated to anti-lung cancer single-chain antibody 2A7-1 has much higher cytotoxic activity than unconjugated adriamycin against human lung adenocarcinoma.
